Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospective real-world study

Abstract Background The addition of anti-CD38 monoclonal antibodies daratumumab to bortezomib, lenalidomide, and dexamethasone (D-VRd) has shown deeper responses in clinical trials. However, real-world data on D-VRd in patients with newly diagnosed MM (NDMM) remain limited in China. This study compa...

Descripción completa

Detalles Bibliográficos

Autores principales:	Lili Cheng, Dong Liang, Jing Jia, Runfeng Zhang, Yang Yang, Peng Liu, Hongli Sun, Xiaoqi Qin, Yanping Ma, Yin Wu, Hua Wang, Junling Zhuang
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMC 2026-03-01
Colección:	BMC Cancer
Materias:	Multiple myeloma Quadruplet regimen High-risk Multi-centered Real-world study
Acceso en línea:	https://doi.org/10.1186/s12885-026-15815-8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!